4.4 Article

Towards antiviral therapies for treating dengue virus infections

期刊

CURRENT OPINION IN PHARMACOLOGY
卷 30, 期 -, 页码 1-7

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2016.06.002

关键词

-

资金

  1. Seeding Drug Discovery Strategic Award from the Wellcome Trust

向作者/读者索取更多资源

Dengue virus is an emerging human pathogen that poses a huge public health burden by infecting annually about 390 million individuals of which a quarter report with clinical manifestations. Although progress has been made in understanding dengue pathogenesis, a licensed vaccine or antiviral therapy against this virus is still lacking. Treatment of patients is confined to symptomatic alleviation and supportive care. The development of dengue therapeutics thus remains of utmost importance. This review focuses on the few molecules that were evaluated in dengue virus-infected patients: balapiravir, chloroquine, lovastatin, prednisolone and celgosivir. The lessons learned from these clinical trials can be very helpful for the design of future trials for the next generation of dengue virus inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据